China Budesonide Market Investigation Report 2018-2022 - ResearchAndMarkets.com

DUBLIN--()--The "Investigation Report on China Budesonide Market, 2018-2022" report has been added to ResearchAndMarkets.com's offering.

It is estimated that the number of asthma patients in China has exceeded 20 million. At present, the main inhaled corticosteroids used in clinical practice are Budesonide, Fluticasone and Beclomethasone.

In 1994, China approved the import of Budesonide. In 1995, Astra (Wuxi) Pharmaceutical was approved to manufacture and sell Budesonide in China. Budesonide has been developing rapidly since it entered the Chinese market. Its annual sales increased from approximately CNY 100 million in 2007 to approximately CNY 1.2 billion in 2017 with the CAGR from 2007 to 2017 up to 27.7%.

There is a high demand for Budesonide in China. The majority of Budesonide currently sold on the market are manufactured by AstraZeneca, Synmosa Biopharma Corporation, Lunan Better Pharmaceutical Co. Ltd., Orion Pharma and Shanghai Sine Pharmaceutical Laboratories Co. Ltd. In terms of sales, AstraZeneca has the highest market share, accounting for more than 90% of the Chinese market in 2017.

Owing to the aggravating environmental pollution and ageing population, China will see a rising incidence of respiratory diseases from 2018 to 2012, which will lead to an ever-expanding Budesonide market.

Companies Featured

  • AstraZeneca
  • Synmosa Biopharma Corporation
  • Lunan Better Pharmaceutical Co. Ltd.
  • Orion Pharma
  • Shanghai Sine Pharmaceutical Laboratories Co. Ltd.

Key Topics Covered

1 Relevant Concepts of Budesonide

1.1 Indications of Budesonide

1.2 Development History of Budesonide in China

1.3 Patent Status and Approval Information of Budesonide in China

2 Sales of Budesonide in China, 2013-2017

2.1 Sales Value of Budesonide

2.1.1 Sales Value of Budesonide in China

2.1.2 Sales Value by Region

2.2 Sales Volume of Budesonide

2.2.1 Sales Volume of Budesonide in China

2.2.2 Sales Volume by Regions

2.3 Sales of Various Dosage Forms of Budesonide in China,2013-2017

2.3.1 Suspensions

2.3.2 Sprays

2.3.3 (Powder) Aerosols

3 Analysis on Major Budesonide Manufacturers in China, 2013-2017

3.1 Analysis on Market Share of Major Budesonide Manufacturers

3.1.1 Market Share by Sales Value

3.1.2 Market Share by Sales Volume

3.2 AstraZeneca

3.2.1 Enterprise Profile

3.2.2 Sales of AstraZeneca's Budesonide in China

3.3 Synmosa Biopharma Corporation

3.4 Lunan Better Pharmaceutical Co., Ltd.

3.5 Orion Pharma

3.6 Shanghai Sine Pharmaceutical Laboratories Co., Ltd.

4 Several Manufacturers' Budesonide Prices on the Chinese Market, 2017-2018

4.1 AstraZeneca

4.2 Synmosa Biopharma Corporation

4.3 Lunan Better Pharmaceutical Co., Ltd.

4.4 Orion Pharma

4.5 Shanghai Sine Pharmaceutical Laboratories Co., Ltd.

5 Prospects of Chinese Budesonide Market, 2018-2022

5.1 Forecast on Market Size

5.2 Forecast on Market Trend

For more information about this report visit https://www.researchandmarkets.com/research/jfzwx3/china_budesonide?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs, Gastrointestinal Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs, Gastrointestinal Drugs